Healthcare provider profile · identity verified

Brian Bourgeault, PA

Physician Assistant · SPRINGFIELD, MA · NPI 1962651604

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	351	95
Trulicity	Dulaglutide	259	45
Gabapentin	Gabapentin	256	48
Amlodipine Besylate	Amlodipine Besylate	238	61
Lisinopril	Lisinopril	223	52
Omeprazole	Omeprazole	167	44
Diclofenac Sodium	Diclofenac Sodium	163	56
Albuterol Sulfate Hfa	Albuterol Sulfate	153	39
Levothyroxine Sodium	Levothyroxine Sodium	116	30
Ventolin Hfa	Albuterol Sulfate	115	27
Metoprolol Succinate	Metoprolol Succinate	112	23
Sertraline Hcl	Sertraline Hcl	100	22
Fluticasone Propionate	Fluticasone Propionate	96	38
Metformin Hcl Er	Metformin Hcl	94	17
Ozempic	Semaglutide	94	16
Hydrochlorothiazide	Hydrochlorothiazide	92	22
Losartan Potassium	Losartan Potassium	90	28
Duloxetine Hcl	Duloxetine Hcl	89	19
Eliquis	Apixaban	83	14
Oxycodone Hcl	Oxycodone Hcl	79	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	77	13
Meloxicam	Meloxicam	74	40
Pregabalin	Pregabalin	71	12
Carvedilol	Carvedilol	70	19
Alcohol Pads	Alcohol Antiseptic Pads	68	14
Trazodone Hcl	Trazodone Hcl	67	19
Comfort Ez Pen Needle	Pen Needle, Diabetic	65	suppressed
Metformin Hcl	Metformin Hcl	65	21
Famotidine	Famotidine	62	16
Jardiance	Empagliflozin	56	14
Quetiapine Fumarate	Quetiapine Fumarate	54	suppressed
Clopidogrel	Clopidogrel Bisulfate	51	suppressed
Farxiga	Dapagliflozin Propanediol	50	12
Pantoprazole Sodium	Pantoprazole Sodium	49	15
Tizanidine Hcl	Tizanidine Hcl	47	15
Tramadol Hcl	Tramadol Hcl	45	16
Hydroxyzine Hcl	Hydroxyzine Hcl	43	16
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	42	suppressed
Simvastatin	Simvastatin	40	11
Wixela Inhub	Fluticasone Propion/Salmeterol	40	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	39	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	39	11
Triamcinolone Acetonide	Triamcinolone Acetonide	36	22
Incruse Ellipta	Umeclidinium Bromide	35	suppressed
Levetiracetam	Levetiracetam	35	suppressed
Allopurinol	Allopurinol	34	suppressed
Ibuprofen	Ibuprofen	34	13
Spironolactone	Spironolactone	33	12
Baclofen	Baclofen	32	19
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	29	suppressed
Furosemide	Furosemide	29	11
Brilinta	Ticagrelor	28	suppressed
Mirtazapine	Mirtazapine	28	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Ammonium Lactate	Ammonium Lactate	25	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	25	suppressed
Montelukast Sodium	Montelukast Sodium	25	suppressed
Oxcarbazepine	Oxcarbazepine	25	suppressed
True Comfort Safety Pen Needle	Pen Needle, Diabetic, Safety	24	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	23	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	23	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Buspirone Hcl	Buspirone Hcl	22	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	21	suppressed
Mounjaro	Tirzepatide	21	suppressed
Oxycontin	Oxycodone Hcl	21	suppressed
Alendronate Sodium	Alendronate Sodium	20	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	20	suppressed
Labetalol Hcl	Labetalol Hcl	20	suppressed
Lidocaine	Lidocaine	20	suppressed
Novolog Flexpen	Insulin Aspart	20	suppressed
Atenolol	Atenolol	19	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Valsartan	Valsartan	18	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	17	suppressed
Comfort Ez Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Lamotrigine	Lamotrigine	17	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Morphine Sulfate	Morphine Sulfate	16	suppressed
Prazosin Hcl	Prazosin Hcl	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Lactulose	Lactulose	14	suppressed
Primidone	Primidone	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Finasteride	Finasteride	12	suppressed
Invega Sustenna	Paliperidone Palmitate	12	suppressed
Invokamet	Canagliflozin/Metformin Hcl	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Potassium Chloride	Potassium Chloride	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Diazepam	Diazepam	11	suppressed
Linzess	Linaclotide	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Nystatin	Nystatin	11	suppressed
Prednisone	Prednisone	11	suppressed
Roflumilast	Roflumilast	11	suppressed
Torsemide	Torsemide	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error